背景:过敏性鼻炎(AR)的发病率正在上升,严重影响生活质量,工作效率,患者的精神状态,在AR睡眠中睡觉。本实验旨在研究AR小鼠模型鼻黏膜中Treg/Th17细胞的变化以及抗IL-17抗体的干预作用。
方法:通过腹腔注射卵清蛋白(OVA)致敏和滴鼻刺激诱导小鼠AR模型。摩擦的时间,打喷嚏,并统计和分析症状学评分。通过苏木精-伊红(HE)染色观察鼻粘膜的病理损伤。采用流式细胞术(FCM)检测外周血CD4+CD25+CD127-Treg细胞水平和Th17细胞含量。采用ELISA试剂盒检测Treg细胞分泌的相关细胞因子(IL-10和TGF-β1)水平。通过给予抗IL-17抗体治疗观察抗IL-17抗体的干预效果。
结果:摩擦次数,打喷嚏,OVA组小鼠的症状学评分明显高于对照组(p<0.001)。CD4+CD25+CD127-Treg细胞在CD4+CD25+T细胞中的百分比(p<0.05),IL-10(p<0.001)和TGF-β1(p<0.001)水平显著降低。OVA诱导后,小鼠鼻粘膜的连续性被中断,Th17细胞的百分比,IL-17和IL-4水平升高,和IFN-γ水平显着降低(p<0.001)。RORγt蛋白表达显著上调(p<0.001)。此外,所有这些结果都被抗IL-17抗体治疗逆转,显著改善AR相关症状(p<0.05)。
结论:抗IL-17抗体可能通过促进CD4+CD25+CD127-Treg细胞分化来调节机体的免疫反应。从而改善与AR相关的症状。
BACKGROUND: The incidence rate of allergic rhinitis (AR) is on the rise, which seriously affects the quality of life, work efficiency, mental state of patients, and sleeping in AR sleep. This experiment aimed to investigate the changes in Treg/Th17 cells in the nasal mucosa of an AR mouse model and the intervention effect of an Anti-IL-17 antibody.
METHODS: A mouse model of AR was induced by intraperitoneal ovalbumin (OVA) injection for sensitization and stimulation with nasal drops. The times of rubbing, sneezing, and symptomatology scores were counted and analyzed. Pathological damage to the nasal mucosa was observed by Hematoxylin-Eosin (HE) staining. Peripheral blood CD4+CD25+CD127- Treg cell levels and the content of Th17 cells were measured by flow cytometry (FCM). ELISA kits were used to detect the levels of relevant cytokines (IL-10 and TGF-β1) secreted by Treg cells. The intervention effect of Anti-IL-17 antibody was observed by giving Anti-IL-17 antibody treatment.
RESULTS: The times of rubbing, sneezing, and symptomatology scores were significantly higher in mice in the OVA group than in the Control group (p < 0.001). The percentage of CD4+CD25+CD127- Treg cells in CD4+CD25+ T cells (p < 0.05) and the levels of IL-10 (p < 0.001) and TGF-β1 (p < 0.001) were significantly decreased. After OVA induction, the continuity of the nasal mucosa of mice was interrupted, the percentage of Th17 cells, IL-17, and IL-4 levels were increased, and IFN-γ levels were significantly reduced (p < 0.001). And protein expression of RORγt was significantly upregulated (p < 0.001). In addition, all of these results were reversed by Anti-IL-17 antibody treatment, significantly improving AR-related symptoms (p < 0.05).
CONCLUSIONS: Anti-IL-17 antibodies may regulate the body\'s immune response by promoting CD4+CD25+CD127- Treg cell differentiation, thereby ameliorating the symptoms associated with AR.